CliffBio
small molecule

MYQORZO

AFICAMTEN

Loss of exclusivityJuly 2042latest FDA-listed patent expiry
CompanyCytokinetics →See this company's full patent-cliff portfolio

Drug detail

Brand nameMYQORZO
Active ingredientAFICAMTEN
Strength15MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2025
Marketing statusRX

Listed patents

PatentExpiresType
12370179July 2042use U-4371
10836755January 2039substance, product

Regulatory exclusivity

CodeExpires
NCEDecember 2030

More from Cytokinetics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.